Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ALMS
$28.08
$
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Next Earnings
2026-02-25
Beta
-2.0252523
Average Volume
Market Cap
Last Dividend
CIK
0001847367
ISIN
US0223071020
CUSIP
022307102
CEO
Martin Babler
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
168
IPO Date
2021-02-22
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS | Credit Industriel ET Commercial lessened its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 36.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 247,002 shares of the company's stock after selling 140,000 shares during the quarter. Credit | Defense World | 2026-02-16 04:19:00 |
| Alumis to Participate in Upcoming February Investor Conferences | SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: | GlobeNewsWire | 2026-02-05 08:05:00 |
| Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. | This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition. | Fool - Investing News | 2026-02-03 09:46:20 |
| Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January | Alumis Inc. (NASDAQ: ALMS - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 8,672,088 shares, a growth of 93.1% from the December 31st total of 4,492,125 shares. Based on an average daily trading volume, of 10,417,053 shares, | Defense World | 2026-01-30 01:22:55 |
| Huge Insider Buying Now at This Insurance Giant and 2 Biotechs | In the past week, a beneficial owner has continued to build a stake in insurance giant W.R. | 24/7 Wall Street | 2026-01-19 08:45:46 |
| An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million | Acquisition of 588,235 shares at $17.00 per share, representing a total transaction value of ~$10.0 million as of Jan. 9, 2026. This purchase represented 46.49% of Srinivas Akkaraju's previously reported indirect holdings. | The Motley Fool | 2026-01-17 13:46:59 |
| David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7 | The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise. | Benzinga | 2026-01-15 16:12:14 |
| Alumis (NASDAQ:ALMS) Trading 6.6% Higher Following Insider Buying Activity | Alumis Inc. (NASDAQ: ALMS - Get Free Report) traded up 6.6% during mid-day trading on Wednesday following insider buying activity. The stock traded as high as $23.94 and last traded at $23.5690. 1,274,140 shares were traded during trading, a decline of 89% from the average session volume of 11,453,423 shares. The stock had previously closed at | Defense World | 2026-01-15 02:08:45 |
| Alumis (NASDAQ:ALMS) Major Shareholder Foresite Labs, Llc Purchases 411,764 Shares | Alumis Inc. (NASDAQ: ALMS - Get Free Report) major shareholder Foresite Labs, Llc purchased 411,764 shares of Alumis stock in a transaction dated Thursday, January 8th. The shares were acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the transaction, the insider directly owned 5,702,536 shares in the company, | Defense World | 2026-01-14 04:48:51 |
| Alumis (NASDAQ:ALMS) Director Srinivas Akkaraju Acquires 588,235 Shares of Stock | Alumis Inc. (NASDAQ: ALMS - Get Free Report) Director Srinivas Akkaraju acquired 588,235 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were purchased at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the acquisition, the director owned 1,853,488 shares | Defense World | 2026-01-14 04:48:47 |
| Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. | GlobeNewsWire | 2026-01-09 16:05:00 |
| Alumis Announces Pricing of Upsized Public Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share. | GlobeNewsWire | 2026-01-07 22:52:00 |
| ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies | Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance. | Zacks Investment Research | 2026-01-07 12:56:08 |
| Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise | Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, with two-thirds achieving PASI 90 and over 40% reaching complete clearance by Week 24. ALMS announced a $175 million public offering to fund regulatory and clinical advancement, with a 2026 NDA submission targeted. | Seeking Alpha | 2026-01-07 11:22:10 |
| Alumis Shares Jump as Envudeucitinib Hits Phase III Endpoints in Psoriasis, NDA Planned for 2026 | Alumis (NASDAQ: ALMS) used a conference call to highlight positive top-line Phase III results for envudeucitinib, its next-generation oral TYK2 inhibitor, in adults with moderate to severe plaque psoriasis. Management said the program met all primary and secondary endpoints with "high statistical significance," showed rapid onset of effect, and delivered deepening skin clearance through 24 weeks | Defense World | 2026-01-07 05:02:48 |
| Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib | Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital. | The Motley Fool | 2026-01-06 17:12:50 |
| Alumis Announces Proposed Public Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock. | GlobeNewsWire | 2026-01-06 16:12:00 |
| Alumis Stock Hits Record High on Psoriasis Drug Trial Results | Biotech stock Alumis Inc (NASDAQ:ALMS) is skyrocketing today, up 107.9% at $17.28 at last glance, after the Johnson & Johnson (JNJ) rival announced its plaque psoriasis drug, envudeucitinib, met all of its primary and secondary endpoints in both of its phase three trials. | Schaeffers Research | 2026-01-06 10:59:00 |
| Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars | Alumis Inc. (NASDAQ: ALMS) stock is trading higher on Tuesday, with a session volume of 4.33 million compared to the average volume of 1.02 million as per data from Benzinga Pro. | Benzinga | 2026-01-06 10:47:31 |
| Alumis skin disease drug meets main goal of two late-stage trials | Alumis said on Tuesday its experimental pill met the main goal in two late-stage studies in patients with a type of skin disease. | Reuters | 2026-01-06 07:07:17 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 5 | 2026-02-11 | 2026-02-11 | View Filing |
| S-8 | 2026-01-30 | 2026-01-30 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-13 | 2026-01-13 | View Filing |
| SC 13D/A | 2026-01-13 | 2026-01-13 | View Filing |
| SC 13D/A | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 4 | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-09 | 2026-01-09 | View Filing |
| 424B5 | 2026-01-08 | 2026-01-08 | View Filing |
| 424B5 | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-04 | 2025-12-04 | View Filing |
| 4 | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| SC 13D | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| SC 13D/A | 2025-11-17 | 2025-11-17 | View Filing |
| SC 13G/A | 2025-11-17 | 2025-11-17 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-09-03 | 2025-09-03 | View Filing |
| EFFECT | 2025-08-20 | 2025-08-20 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-04 | 2025-08-04 | View Filing |
| 4 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-14 | 2025-07-14 | View Filing |
| 3 | 2025-07-14 | 2025-07-14 | View Filing |
| S-3 | 2025-07-03 | 2025-07-03 | View Filing |
| 8-K/A | 2025-06-30 | 2025-06-30 | View Filing |
| ARS | 2025-06-16 | 2025-06-16 | View Filing |
| DEFA14A | 2025-06-16 | 2025-06-16 | View Filing |
| DEF 14A | 2025-06-16 | 2025-06-16 | View Filing |
| S-8 | 2025-06-10 | 2025-06-10 | View Filing |
| SC 13D/A | 2025-06-10 | 2025-06-10 | View Filing |
| SC 13D/A | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| SC 13D/A | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 3 | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-21 | 2025-05-21 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13D/A | 2025-05-07 | 2025-05-07 | View Filing |
| 4 | 2025-05-06 | 2025-05-06 | View Filing |
| 4 | 2025-05-06 | 2025-05-06 | View Filing |
| 4 | 2025-05-06 | 2025-05-06 | View Filing |
| 4 | 2025-05-06 | 2025-05-06 | View Filing |
| 425 | 2025-04-29 | 2025-04-29 | View Filing |
| EFFECT | 2025-04-24 | 2025-04-24 | View Filing |
| 424B3 | 2025-04-23 | 2025-04-23 | View Filing |
| 10-K/A | 2025-04-23 | 2025-04-23 | View Filing |
| S-4 | 2025-04-21 | 2025-04-21 | View Filing |
| 425 | 2025-04-21 | 2025-04-21 | View Filing |
| 425 | 2025-04-21 | 2025-04-21 | View Filing |
| 425 | 2025-04-21 | 2025-04-21 | View Filing |
| 8-K | 2025-04-21 | 2025-04-21 | View Filing |
| EFFECT | 2025-04-07 | 2025-04-07 | View Filing |
| 425 | 2025-04-04 | 2025-04-04 | View Filing |
| 424B3 | 2025-04-04 | 2025-04-04 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| S-4/A | 2025-04-02 | 2025-04-02 | View Filing |
| S-4 | 2025-03-27 | 2025-03-27 | View Filing |
| 425 | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| S-8 | 2025-03-19 | 2025-03-19 | View Filing |
| 425 | 2025-03-19 | 2025-03-19 | View Filing |
| 10-K | 2025-03-19 | 2025-03-19 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Weighted Momentum Strategy | 118.87% | 0.63 | 6 | 0.05 | 0.14 | 68.22 |
| Macd Rsi Composite Strategy | 110.99% | 0.9 | 29 | 0.06 | 0.18 | 60.34 |
| Adaptive Wave | 102.43% | 1.51 | 5 | 0.04 | 0.11 | 51.78 |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |